العلاج الجهازي من الخط الثاني لسرطان القناة الصفراوية خارج الكبد غير القابل للاستئصال أو النقيلي بدون تغيير جزيئي قابل للاستهداف

References

In the absence of targetable alterations, FOLFOX should be offered as a subsequent line of systemic therapy for patients diagnosed with advanced eCCA who have tumour progression on first-line therapy. Alternatives to consider include irinotecan-based options (based on phase II trial data) (LoE 2, strong recommendation, consensus).

Upon progression to first-line chemotherapy, second-line chemotherapy options for biliary tract tumours include FOLFOX and liposomal irinotecan and 5-fluorouracil (NalIRI+5FU).